BEFORE THE FINANCE SUBCOMMITTEE OF THE INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE

ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

LOCATION: AS AGENDIZED

DATE: JUNE 19, 2008

3: 30 P. M.

REPORTER: BETH C. DRAIN, CSR

CSR. NO. 7152

BRS FILE NO.: 81777

INDEX

ITEM NO.	DESCRI PTI ON	PAGE
CALL TO ORDER	2	3
ROLL CALL		3
CONSI DERATI ON	N OF CIRM 2008-2009 BUDGET	4
	PRESENTATION AND DISCUSSION POLICIES FOR CIRM LOAN PROGRAM	31
ADJOURNMENT		40

2

	DARRISTERS REPORTING SERVICE
1	COSTA MESA, CALIFORNIA; THURSDAY, MAY 19, 2008
2	3: 30 P. M.
3	
4	CHAIRMAN GOLDBERG: I'D LIKE TO CALL THE
5	MEETING TO ORDER. I'D ALSO LIKE TO SAY TO MEMBERS
6	OF THE PUBLIC THAT WHEN WE GET TO OPEN SESSION,
7	WE'LL HAVE A TWO-MINUTE RESTRICTION ON QUESTIONS AND
8	ANSWERS. MELISSA.
9	MS. KING: RICARDO AZZIZ.
10	DR. AZZI Z: PRESENT.
11	MS. KING: ROBERT PRICE FOR ROBERT
12	BI RGENEAU.
13	DR. PRICE: PRESENT.
14	MS. KING: FLOYD BLOOM.
15	DR. BLOOM: HERE.
16	MS. KING: MARCY FEIT. MICHAEL GOLDBERG.
17	CHAIRMAN GOLDBERG: HERE.
18	MS. KING: BOB KLEIN.
19	MR. KLEIN: HERE.
20	MS. KING: TED LOVE. TINA NOVA.
21	DR. NOVA: HERE.
22	MS. KING: ED PENHOET. PHIL PIZZO. DUANE
23	ROTH.
24	MR. ROTH: HERE.
25	MS. KING: JEFF SHEEHY.
	3

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

_	
1	MR. SHEEHY: HERE.
2	MS. KING: OSWALD STEWARD. OSWALD
3	STEWARD. IS YOUR PHONE MUTED, DR. STEWARD?
4	DR. STEWARD: YES, IT IS. I'M SORRY.
5	HERE.
6	MS. KING: AND, JAMES HARRISON, I BELIEVE
7	THAT MEANS WE HAVE A QUORUM, CORRECT?
8	MR. HARRISON: WE DO INDEED.
9	CHAIRMAN GOLDBERG: I'D LIKE TO CONSIDER
10	AGENDA ITEM NO. 3, THE PROPOSED CIRM BUDGET FOR 2008
11	AND 2009. WE ARE HOPEFUL THAT AT EACH SITE THERE
12	ARE COPIES OF THAT BUDGET AVAILABLE. THE BUDGET WAS
13	MADE AVAILABLE ON LINE IN ADVANCE AS WELL.
14	AND TO PROVIDE A CONTEXT FOR THE BUDGET,
15	I'D SIMPLY LIKE TO START BY OUTLINING A PROPOSED
16	PROCESS, WHICH WOULD BE THAT WE HAVE MARGARET
17	FERGUSON WALK US THROUGH THE BUDGET ONCE WITHOUT
18	INTERRUPTION AND WITHOUT QUESTION, A SECOND TIME
19	WITH QUESTIONS FROM THE BOARD, A THIRD TIME WITH
20	QUESTIONS FROM THE PUBLIC, AND THEN FINALLY A PERIOD
21	OF OPEN DISCUSSION FOR BOTH THE SUBCOMMITTEE AND THE
22	PUBLIC TO COMMENT OR ASK QUESTIONS MORE GLOBALLY
23	ABOUT THE BUDGET ITSELF.
24	WITH THAT, I'LL TURN IT OVER TO MARGARET
25	AND ASK HER TO OUTLINE THE PROCESS BY WHICH WE

1	ARRIVED AT THE BUDGET WHICH IN MY VIEW IS QUITE WELL
2	DONE.
3	MS. FERGUSON: THANK YOU. THE APPROACH
4	THAT I TOOK OR THAT WAS TAKEN TO PREPARE THIS
5	PROPOSED BUDGET WAS THIS IS MARGARET FERGUSON,
6	AND I'M GOING TO GO OVER THE APPROACH THAT WAS TAKEN
7	TO PREPARE THE BUDGET, AND THEN WE'LL TALK ABOUT THE
8	PROPOSED BUDGET ITSELF.
9	IN PREPARING THE BUDGET, I STARTED WITH
10	THE '07-'08 UPDATED BUDGET THAT WAS REVIEWED AT THE
11	MARCH ICOC MEETING AS MY BASELINE. I GARNERED
12	INFORMATION FROM THE VARIOUS COST CENTERS, WHICH
13	WOULD BE THE SCIENCE OFFICE, THE OFFICE OF
14	ADMINISTRATION, THE OFFICE OF THE PRESIDENT, THE
15	OFFICE OF THE CHAIR, REVIEWED AND COMPILED THAT
16	INFORMATION INTO WHAT IS NOW THE PROPOSED BUDGET.
17	I ALSO SPOKE WITH OUR LEGAL STAFF IN TERMS
18	OF CONTRACTS OR PROPOSED CONTRACTS AND HUMAN
19	RESOURCES ON POSITIONS.
20	MOVING ON TO THE ACTUAL CHART, I'LL GO TO
21	THE TOP HEADINGS, WHICH IT'S BROKEN OUT BY EACH OF
22	THE COST CENTERS WITH A TOTAL. THE FIRST COST
23	CENTER IDENTIFIED IS THE SCIENCE OFFICE. OOA
24	REPRESENTS THE OFFICE OF ADMINISTRATION; OOP IS THE
25	OFFICE OF THE PRESIDENT; OOC IS THE OFFICE OF THE
	E

1	CHAIR, AND OOVCP IS THE OFFICE OF THE VICE
2	CHAIR-PRESIDENT WITH A TOTAL PROPOSED BUDGET FOR
3	'08-'09. THERE'S ALSO ON THE CHART THE UPDATED
4	'07-'08 BUDGET, WHICH WAS MY STARTING POINT, AND A
5	DIFFERENCE, THE VARIANCE, BETWEEN THE TWO BUDGETS
6	AND THE PERCENTAGE INCREASES OR CHANGES.
7	AT THE VERY TOP OF THE CHART, YOU WILL SEE
8	THAT THE STAFF FOR '08-'09 AS IT IS CURRENTLY OR
9	PROPOSED TO BE ALLOCATED AMONG THE DIFFERENT COST
10	CENTERS, THE '07-'08 STAFFING ALLOCATION AMONG THE
11	COST CENTERS. THE FIRST MAJOR CATEGORY, WHICH IS
12	SALARIES AND BENEFITS, AT THIS POINT THE PROPOSAL IS
13	3.4, AND I'LL JUST ROUND EVEN MORE RIGHT NOW, 3.4
14	FOR THE SCIENCE OFFICE TO SUPPORT THE PROPOSED 25
15	POSITIONS, 1.8 IN THE OFFICE OF ADMINISTRATION TO
16	SUPPORT THE 12 PROPOSED POSITIONS IN ADMINISTRATION,
17	720,000 FOR THE OFFICE OF THE PRESIDENT IN SUPPORT
18	OF TWO POSITIONS; OFFICE OF THE CHAIR, 723,000 IN
19	SUPPORT OF 4.5 PERSONNEL YEARS OF POSITIONS.
20	OBVIOUSLY IT CAN'T BE A HALF A PERSON. AND ONE
21	POSITION IS ALLOCATED FOR THE OFFICE OF THE VICE
22	CHAIR WITH NO FUNDING AT THIS POINT IN TIME BECAUSE
23	THE FUNDING IS AT THIS MOMENT PART OF AN INTERAGENCY
24	AGREEMENT I'M SORRY EXTERNAL CONTRACT, FOR
25	TOTAL SALARIES AND BENEFITS OF \$6.7 MILLION.

1	INTERAGENCY AGREEMENTS, AT THIS POINT
2	THERE ARE ONLY TWO COST CENTERS WITH INTERAGENCY
3	AGREEMENTS, OFFICE OF ADMINISTRATION AND OFFICE OF
4	THE CHAIR. EXTERNAL CONTRACTS ARE 682,000 IN THE
5	SCIENCE OFFICE, 1.1 MILLION IN THE OFFICE OF
6	ADMINISTRATION, A HUNDRED THOUSAND FOR THE OFFICE OF
7	THE PRESIDENT, AND 615,000 IN OFFICE OF THE CHAIR,
8	WITH THE 275,000 IN THE OFFICE OF THE VICE CHAIR.
9	ICOC MEETINGS, THAT'S IN SUPPORT OF
10	MEETINGS THAT ARE PUT ON OR MEETINGS OR TRAVEL TO
11	MEETINGS FOR THE ICOC. 10,000 WAS RESERVED IN THE
12	SCIENCE OFFICE WITH 267,000 IN THE OFFICE OF THE
13	CHAIR. SCIENTIFIC MEETINGS, 498,000 IN SCIENCE
14	OFFICE, 11 IN OFFICE OF ADMINISTRATION, AND 15 IN
15	OFFICE OF THE CHAIR. AND I'M SORRY, BUT THE
16	TOTAL I NEGLECTED TO SAY THE TOTALS THERE ARE AT
17	THE RIGHT-HAND SIDE OF THE COLUMN UNDER PROPOSED
18	2008-09 OF 524,000.
19	THEN WE HAVE MONIES SET ASIDE FOR OR
20	ALLOCATED FOR WORK GROUP GRANTS OF 560,000 IN THE
21	SCIENCE OFFICE, THE WORK GROUP STANDARDS OF 160,000
22	IN OFFICE OF ADMINISTRATION; WORK GROUP FACILITIES
23	FOR WRAP-UP, 51,000; OTHER TRAVEL, WHICH IS A
24	COMBINATION OF IN-STATE, REGULAR IN-STATE TRAVEL FOR
25	CIRM STAFF AS WELL AS OUT-OF-CALIFORNIA TRAVEL FOR
	_

1	CIRM STAFF. THAT'S IN OFFICE OF THE CHAIR.
2	FURNITURE AND EQUIPMENT, A MINOR AMOUNT OF
3	\$38,000; INFORMATION TECHNOLOGY, \$53,000; AND OTHER
4	OPERATING EXPENSE AND EQUIPMENT, 209,000 IN THE
5	SCIENCE OFFICE, 363,000 IN OFFICE OF ADMINISTRATION,
6	213 IN OFFICE OF THE PRESIDENT, 107 IN THE OFFICE OF
7	THE CHAIR FOR A TOTAL \$893,000.
8	AT THE VERY BOTTOM, THE VERY NEXT ROW,
9	WHICH SAYS TOTAL 2008-9, THAT IS THE TOTAL PROPOSED
10	BUDGET BY COST CENTER. 5.6 FOR THE SCIENCE OFFICE,
11	3.9 FOR OFFICE OF ADMINISTRATION, 1.1 FOR OFFICE OF
12	THE PRESIDENT, AND 2 POINT OR A LITTLE OVER 2
13	MILLION FOR OFFICE OF THE CHAIR, WITH 288,000 FOR
14	OFFICE OF THE VICE CHAIR.
15	THE 2007-8 COST CENTER ALLOCATIONS ARE
16	LISTED RIGHT BELOW FOR A TOTAL OF 8.9 MILLION, WHICH
17	IS THE UPDATED OR THE CURRENT BUDGET THAT WE'RE
18	WORKING WITH WITH THE DIFFERENCES BY COST CENTER
19	LISTED NEXT.
20	UNDER THE FUND ALLOCATIONS PER THE
21	PROPOSITION 71, THAT IS A DISTRIBUTION OF WHERE THE
22	EXPENDITURES WILL BE REFLECTED FOR THIS PROPOSED
23	BUDGET. GENERAL ADMINISTRATION MONEY, WHICH IS 2.5
24	MILLION UNDER OFFICE OF ADMINISTRATION; 1.1 UNDER
25	OFFICE OF THE CHAIR; AND 1.3 I'M SORRY OFFICE

1	OF THE PRESIDENT, THEN 1.3 UNDER OFFICE OF THE CHAIR
2	FOR A TOTAL OF APPROXIMATELY \$5 MILLION, WHICH IS
3	CURRENTLY WELL BELOW THE 3-PERCENT CAP IF WE WERE
4	USING AN AVERAGE OF \$9 MILLION FOR GENERAL
5	ADMINISTRATION UNDER THE PROVISIONS OF PROP 71.
6	GRANTS ADMINISTRATION, 5.6 MILLION WILL BE
7	CHARGED FOR THE SCIENCE OFFICE; 574,000 UNDER OFFICE
8	OF ADMINISTRATION, FOR A TOTAL OF 6.2 MILLION.
9	AGAIN, WELL UNDER THE \$9 MILLION CAP IF WE WERE
10	USING AN AVERAGE FOR THE 3 PERCENT.
11	DIRECT RESEARCH IS WHAT WILL BE ALLOCATED
12	IS 805,000 UNDER THE OFFICE OF ADMINISTRATION,
13	694,000 FOR OFFICE OF THE CHAIR, AND 288 UNDER
14	OFFICE OF THE VICE CHAIR, AND THAT IS FOR LEGAL
15	COSTS THAT ARE ALLOWED TO BE CHARGED UNDER DIRECT
16	RESEARCH IN ACCORDANCE WITH PROP 71 GUIDELINES.
17	THE MAJOR DIFFERENCES RIGHT NOW BETWEEN
18	THE OR THE CHANGES BETWEEN THE '07-'08 UPDATED
19	BUDGET AND THE PROPOSED '08-'09 BUDGET, IF WE TAKE
20	THE MAJOR CATEGORIES OF SALARIES AND BENEFITS, THE
21	CHANGES THERE OR THE INCREASES ARE A RESULT OF THE
22	INCREASE IN PROPOSED POSITIONS, WITH THOSE POSITIONS
23	BEING IN THE SCIENCE OFFICE FOR THE MOST PART. I
24	BELIEVE IT WAS SIX POSITIONS THAT ARE PROPOSED. YOU
25	WILL SEE THAT ON THE PROPOSED NEW POSITIONS TABLE.

1	AND ONE ADDITIONAL POSITION IN OFFICE OF
2	ADMINISTRATION.
3	CALCULATED IN THAT CHANGE AS WELL WOULD BE
4	AN ALLOWANCE FOR PERFORMANCE AWARDS, MERIT AWARDS,
5	AND COST OF LIVING INCREASE. AND, AGAIN, THAT IS
6	JUST A PROPOSED ALLOWANCE AND UNDER THE GUIDELINES
7	OF ICOC POLICY.
8	CHAIRMAN GOLDBERG: MARGARET, THAT WAS A
9	VERY HELPFUL OVERVIEW. WHY DON'T WE GO FIRST TO
10	MEMBERS OF THE SUBCOMMITTEE BY SITE, AND THEN WE'LL
11	CIRCULATE FOR QUESTIONS TO MEMBERS OF THE PUBLIC BY
12	SITE. CHAIRMAN KLEIN.
13	MR. KLEIN: WELL, MARGARET, WHAT I'D LIKE
14	TO DO IS PROVIDE SOME PERSPECTIVE FOR THE PUBLIC AND
15	THE MEMBERS ON THE OVERALL BUDGET NUMBER, WHICH IS A
16	SIGNIFICANT INCREASE. AS YOU'VE CALLED TO OUR
17	ATTENTION, WE HAVE A SUBSTANTIAL INCREASE IN THE
18	SIZE OF THE SCIENTIFIC STAFF, WHICH IS ADDING
19	SIGNIFICANTLY TO THE NUMBER OF SCIENTIFIC STAFF
20	MEMBERS THAT WE NEED TO SEND TO CONFERENCES SO THAT
21	WE MAKE CERTAIN THAT WE ARE LEARNING GLOBALLY AND
22	AVOIDING DUPLICATION. WE DON'T WANT TO FUND WORK
23	THAT THERE'S POSTERS PRESENTED ON AND PRESENTATIONS
24	MADE WHERE, ON THE OTHER HAND, IN PEER REVIEW WE
25	WANT OUR SCIENCE TEAM TO BE AWARE OF THESE BREAKING

1	AREAS SO THAT WE UNDERSTAND THAT SOME THINGS ARE
2	FEASIBLE THAT ARE NOT CONSIDERED PREVIOUSLY TO BE
3	FEASI BLE.
4	SO WE REALLY NEED TO BE ON THE HAVE OUR
5	SCIENCE TEAM HAVE ACCESS TO THE LEADING EDGE OF
6	KNOWLEDGE IN THE FIELD AND GIVE THEM THE ABILITY TO
7	TRAVEL IN THE UNITED STATES AND OUTSIDE THE UNITED
8	STATES TO KEEP UP WITH THAT.
9	SECONDLY, IN LEVERAGING OUR INTELLECTUAL
10	ASSETS, AT THE BIOCONFERENCE, AS A NUMBER OF THE
11	MEMBERS ON THIS COMMITTEE ARE AWARE, WE JUST
12	ANNOUNCED A MEMORANDUM OF UNDERSTANDING WITH CANADA
13	ON CANCER STEM CELL RESEARCH AND WITH STATE OF
14	VICTORIA ON STEM CELL RESEARCH GENERALLY TO DEVELOP
15	COLLABORATI VE RELATI ONSHI PS.
16	CANADA HAS PLEDGED TO FUNDING ON THEIR
17	SIDE \$100 MILLION. ALL OF THESE ANY
18	COLLABORATION WILL HAVE TO GO THROUGH OUR PEER
19	REVIEW. WE'LL ONLY FUND IN CALIFORNIA, BUT IT GIVES
20	US THE ABILITY TO LEVERAGE OUR FUNDS BECAUSE TO THE
21	EXTENT THAT THERE IS CANCER RESEARCH AS PART OF A
22	DISEASE TEAM RFA, FOR EXAMPLE, THAT IS BEING DONE IN
23	CANADA BECAUSE THE CALIFORNIA TEAM HAS REACHED OUT
24	TO SPECIAL EXPERTISE IN CANADA, THEY CAN BE FUNDED
25	THROUGH CANADA, AND THERE WILL BE TRAVEL INVOLVED
	11

1	FOR THE SCIENTIFIC STAFF, ADMINISTRATIVE STAFF, AND
2	AT TIMES MY TRAVEL IS INVOLVED IN THE IMPLEMENTATION
3	OF THESE MEMORANDA OF UNDERSTANDING.
4	AS A CONSEQUENCE OF THE INTERNATIONAL
5	CONFERENCE OF THE INTERNATIONAL STEM CELL FORUM,
6	THERE IS A MEMORANDUM OF UNDERSTANDING IN PROGRESS
7	WITH THE MEDICAL RESEARCH COUNCIL OF ENGLAND AS
8	WELL, NOT SURE IF IT'S ENGLAND, THE BRITISH EMPIRE,
9	TO WHAT LEGAL SOVEREIGN DIVISION THAT THEY ASCRIBE
10	THEIR AUTHORITY AT THIS POINT, BUT THE MEDICAL
11	RESEARCH COUNCIL IS THE OTHER PARTY, THE
12	COUNTERPARTY IN THAT.
13	WE HAVE ALSO AN OPPORTUNITY WITH SPECIFIC
14	DISEASE-RELATED FOUNDATIONS TO OBTAIN MATCHING FUNDS
15	THAT WILL STRETCH OUR RESOURCE FUNDING FURTHER.
16	AGAIN, ALL OF THESE ARE SUBJECT TO OUR REGULAR
17	RFA'S. IT'S SUBJECT TO GOING THROUGH OUR PEER
18	REVIEW PROCESS AND COMING TO OUR BOARD. IT'S JUST
19	ANOTHER SOURCE OF FUNDING.
20	FINALLY, IF THERE IS A DIFFERENT
21	ADMINISTRATION OR DIFFERENT CONGRESSIONAL
22	COMPOSITION NEXT YEAR, THERE IS A POTENTIAL FOR
23	FURTHER NIH FUNDING, ALTHOUGH THE FINANCIAL PICTURE
24	OF THE COUNTRY WILL MAKE ANY SUBSTANTIAL INCREASE
25	DIFFICULT. IT IS POSSIBLE. AND IF THERE ARE 60
	40

1	VOTES IN THE U.S. SENATE SO THAT WE COULD HAVE
2	CLOTURE ON DEBATE, WE MAY ACTUALLY HAVE A CHANGE IN
3	RULES ON EMBRYONIC STEM CELL RESEARCH. IF NOT, AT
4	LEAST VERY POTENTIALLY WE CAN HAVE MORE NIH FUNDING
5	FOR ADULT STEM CELLS AND HAVE COLLABORATION WITH NIH
6	INSTITUTES WHERE THEY CAN PROVIDE POTENTIALLY
7	FUNDING TO US ON GRANTS THAT GO THROUGH OUR PEER
8	REVIEW SYSTEM TO AUGMENT ADULT STEM CELL RESEARCH
9	THAT WE CAN FUND.
10	SO ALL OF THESE AMOUNT TO LEVERAGING OUR
11	INTELLECTUAL ASSETS, LEVERAGING OR FINANCIAL ASSETS,
12	AND LEARNING GLOBALLY. IT'S A VERY COST-EFFECTIVE
13	WAY OF AVOIDING DUPLICATION AND MAKING SURE THAT
14	WE'RE ON THE LEADING EDGE OF STEM CELL RESEARCH
15	GLOBALLY. AND WE CERTAINLY, WITH THE DEDICATION OF
16	THE SCIENTIFIC TEAM, NEED TO MAKE SURE THAT THE
17	PRESIDENT AND THE CHIEF SCIENTIFIC OFFICER AND THE
18	DIRECTOR OF SCIENTIFIC ACTIVITIES HAVE THE ABILITY
19	TO SEND OFFICERS TO THESE LEADING CONFERENCES TO
20	ACCOMPLISH THIS GOAL.
21	SO THAT'S CONTEXT, I THINK, FOR THIS
22	CHANGE IN TRAVEL. IS THAT APPROPRIATE?
23	MS. FERGUSON: THAT IS MOST APPROPRIATE.
24	MR. SHEEHY: I JUST HAD A COUPLE OF
25	THINGS. FIRST OF ALL, JUST FOR THE OE&E, WHAT

1	TYPES?
2	MS. FERGUSON: THE TYPES OF THINGS THAT
3	ARE UNDER
4	MR. SHEEHY: IT DOESN'T NEED TO BE
5	ENCYCLOPEDIC, BUT JUST HAVE A SENSE.
6	MS. FERGUSON: UNDER OE&E, YOU WOULD HAVE
7	ANY COST FOR RIGHT NOW THERE ARE THE MEMBERSHIPS
8	WHERE WE ARE PARTICIPATING IN INTERNATIONAL WHEN WE
9	PAY FOR INTERNATIONAL PARTICIPATION IN SCIENTIFIC
10	GROUPS. THERE IS YOUR GENERAL OFFICE SUPPLIES.
11	THERE IS THIS PARTICULAR OE&E IS MOSTLY MADE UP
12	OF THE MEMBERSHIPS, GENERAL SUPPLIES, TRAINING. AND
13	WHEN I SAY TRAINING, I MEAN PERSONAL DEVELOPMENT
14	TRAINING. COST TO PRODUCE THE ANNUAL REPORTS.
15	THAT'S PRETTY MUCH GENERALLY THAT'S WHAT IT IS.
16	MR. KLEIN: IN THAT REGARD, I THINK THAT
17	IT IS THE INFORMATION IS OUT THERE THAT
18	CALIFORNIA IS UNDER FINAL CONSIDERATION TO BE
19	DESIGNATED OR HAS BEEN DESIGNATED FOR THE ISSCR
20	CONFERENCE THE YEAR AFTER NEXT. SO THAT LOOKING
21	FORWARD IN 2010, COINCIDENTALLY THE SAME YEAR THAT
22	ALL OF THE MAJOR FACILITIES ARE GOING TO OPEN IN
23	CALIFORNIA, THE NEW STEM CELL FACILITIES WE JUST
24	FUNDED, THERE WILL BE A CONFERENCE DESIGNATED FOR
25	SAN FRANCISCO. THE HOPE TO BRING A TREMENDOUS
	1.4

1	AMOUNT OF GLOBAL COLLABORATION AND KNOWLEDGE TO SAN
2	FRANCISCO AS A RETURN FROM THE CONFERENCE THAT WAS
3	HERE IN 2005.
4	CHAIRMAN GOLDBERG: CONTINUING ON WITH
5	QUESTIONS FROM OTHER ANOTHER QUESTION FROM JEFF
6	SHEEHY. THEN I'M GOING TO GO TO YOU IN LA JOLLA,
7	FLOYD.
8	DR. BLOOM: I HAVE NO QUESTIONS.
9	MR. SHEEHY: I JUST WANTED TO REITERATE
10	WHAT BOB WAS MENTIONING ABOUT THE IMPORTANCE OF
11	TRAVEL BECAUSE I KNOW, HAVING READ THE BLOGS, I KNOW
12	MR. SIMPSON IS ON THE PHONE, AND I READ HIS
13	RELEASES. AS SOMEONE WHO IS PREPARING TO GO TO
14	MEXICO CITY IN AUGUST FOR THE INTERNATIONAL AIDS
15	CONFERENCE AND LEAVE MY DARLING DAUGHTER, AND I LOVE
16	MEXICO CITY, BUT, YOU KNOW, THESE CONFERENCES ARE
17	VERY IMPORTANT KEEPING AT THE CUTTING EDGE OF
18	SCIENCE. I KNOW A LOT OF PEOPLE HERE TRAVEL, AND
19	THEY THINK JUNKET AND PARTIES AND ROCK AND ROLL, BUT
20	THIS IS REALLY WORK. AND THIS IS A VERY AND MANY
21	TIMES THIS IS A SACRIFICE ON BEHALF OF STAFF TO
22	ATTEND THESE THINGS.
23	YOU KNOW, THE INTERNATIONAL STEM CELL
24	CONFERENCE WAS IN PHILADELPHIA. I'M SURE IT'S A
25	LOVELY CITY, BUT I DON'T THINK THAT'S THE TOP OF

1	EVERYBODY'S LIST OF VACATION SPOTS. SO I APPLAUD
2	OUR TEAM FOR THE WILLINGNESS TO STAY TO DO THIS
3	TRAVEL AND TO STAY AT THE FOREFRONT OF THE KNOWLEDGE
4	THAT WE NEED TO HAVE TO REALLY DO THE SCIENCE. I
5	THINK THE OBJECTIONS ARE NOT NECESSARILY WELL
6	FOUNDED.
7	CHAIRMAN GOLDBERG: TINA?
8	DR. NOVA: I HAVE NO QUESTIONS. THANK
9	YOU.
10	CHAIRMAN GOLDBERG: DUANE?
11	MR. ROTH: YES. I WANT TO KNOW JUST A
12	COUPLE THINGS ON THE SALARIES, NEW HIRES THAT ARE IN
13	HERE, THE CALCULATION, OR DID YOU BUILD IN THE FACT
14	THAT THERE'S GOING TO BE TURNOVER AND VACANCIES?
15	MS. FERGUSON: I DIDN'T HEAR THE QUESTION.
16	MR. KLEIN: I THINK YOU ARE ASKING, DUANE,
17	SINCE YOU CUT OUT, WHETHER YOU'VE BUDGETED FOR A
18	FULL YEAR, OR DID YOU TAKE INTO ACCOUNT PARTIAL YEAR
19	TURNOVERS AND OTHER THINGS OF THAT KIND.
20	MS. FERGUSON: WE TOOK INTO ACCOUNT
21	PARTIAL YEARS, WHEN AN INDIVIDUAL WAS EXPECTED TO BE
22	BROUGHT ON BOARD, AND WE BUDGETED AT THAT POINT.
23	MR. ROTH: OKAY. AND THEN THE SECOND
24	QUESTION, AND IT'S MORE A COMMENT, ON THE SCIENCE
25	MEETINGS COMBINED WITH THE TRAVEL, BOTH OF THOSE
	14

1	NUMBERS ARE SIGNIFICANTLY HIGHER THAN THE PREVIOUS
2	YEAR. I MEAN THEY'RE VERY MUCH INCREASED. AND
3	WHILE WE DON'T HAVE THE DETAIL ABOUT ALL THE
4	ASSUMPTIONS THAT WENT INTO THAT, I GUESS THE
5	QUESTION, AND THIS IS REALLY I DON'T KNOW WHO TO
6	DIRECT IT AT, BUT IS THIS GOING TO CONTINUE, OR IS
7	THIS A LEVEL OF TRAVEL WE SHOULD EXPECT NOW THAT
8	WE'RE AT FULL FORCE?
9	MR. KLEIN: WELL, WE'RE NOT YET AT FULL
10	FORCE, DUANE. MY UNDERSTANDING MAYBE I SHOULD
11	CHECK. MARGARET, WE'RE AT ABOUT 34?
12	MS. FERGUSON: WE ARE PROPOSED TO BE
13	CHAIRMAN GOLDBERG: AT 44.
14	MS. FERGUSON: 44.
15	MR. KLEIN: BUT WE'RE RIGHT NOW
16	MS. FERGUSON: RIGHT NOW WE'RE AT 37.
17	MR. KLEIN: 37, AND WE WILL BE AT 44
18	DURING THIS NEXT YEAR.
19	MS. FERGUSON: RIGHT.
20	MR. KLEIN: DID SOMEONE JUST JOIN?
21	MS. FEIT: IT'S MARCY FEIT.
22	MR. KLEIN: HI, MARCY.
23	MS. FEIT: SORRY I'M LATE.
24	MR. KLEIN: NOT A PROBLEM. THIS IS BOB
25	KLEIN SPEAKING. THE MIC WILL GO OVER TO THE
	17

1	CHAIRMAN, WHO HAS A DISCUSSION GOING ON THE BUDGET
2	ITEMS. AND DUANE HAS A QUESTION PENDING ABOUT
3	WHETHER THE SCIENTIFIC MEETINGS, WHICH IS A
4	SUBSTANTIAL INCREASE, AND THE TRAVEL IS GOING TO BE
5	NOW AT A FAIRLY LEVEL AREA.
6	DUANE, JUST AS ONE INPUT INTO THAT, I
7	WOULD SAY THAT THERE ARE A NUMBER OF OTHER COUNTRIES
8	THAT ARE PROPOSING OR HAVE DISCUSSED WITH DR.
9	TROUNSON MEMORANDUMS OF UNDERSTANDING. IF THEY CAN
10	BRING 50 OR A \$100 MILLION TO BEAR, IF OUR TRAVEL
11	INCREMENTALLY INCREASES TO REACH OUT FOR THOSE
12	OPPORTUNITIES, IT WOULD CERTAINLY LEVERAGE OUR
13	ASSETS SUBSTANTIALLY. BUT I WOULD GUESS THAT OTHER
14	THAN NEW MAJOR FINANCIAL OPPORTUNITIES THAT INCREASE
15	OUR FUNDING CAPACITY, THAT YOU'VE SEEN THE GREATEST
16	PERCENTAGE INCREASE, AND THE PERCENTAGE INCREASES IN
17	THE FUTURE WOULD BE SMALLER.
18	MR. ROTH: OKAY. THANKS. THAT'S WHAT I
19	WANTED TO KNOW. AND THE NEXT ONE DEALS WITH
20	EXTERNAL CONTRACTS ARE DOUBLED.
21	CHAIRMAN GOLDBERG: YOUR QUESTION, DUANE?
22	MR. KLEIN: THE EXTERNAL CONTRACTS, HE
23	SAID, WERE DOUBLED.
24	MR. ROTH: 50-PERCENT INCREASE.
25	MR. KLEIN: YOU MEAN 50 PERCENT, NOT
	18

1	DOUBLE.
2	MR. ROTH: I WAS JUST LOOKING AT THE
3	50-PERCENT INCREASE OVER THE PREVIOUS YEAR. AND
4	JUST A QUICK COMMENT ABOUT WHAT'S ENTAILED THERE.
5	CHAIRMAN GOLDBERG: MARGARET, WOULD YOU
6	LIKE TO ADDRESS IT?
7	MS. FERGUSON: YES, I WOULD. THE
8	INCREASES ARE, A GOOD PORTION OF IT IS THE ROLLOUT
9	OF THE GRANTS MANAGEMENT SYSTEM, WHICH ACTUALLY
10	STARTED IN '07-'08, BUT MOST OF THAT FUNDING WILL BE
11	PUSHED FORWARD INTO '08-'09 WHEN WE PROPOSE TO ROLL
12	OUT THE GRANT MANAGEMENT SYSTEM. TOGETHER WITH THAT
13	WE HAVE ALSO PROPOSED ALLOCATING A PORTION OF MONEY
14	FOR COMMUNICATIONS AS WELL AS LEGAL SERVICES,
15	INCREMENTAL CHANGES IN LEGAL SERVICES, BUT THE
16	MAJORITY OF IT IS REALLY THE ROLLOUT OF THE GRANTS
17	MANAGEMENT SYSTEM AND COMMUNICATIONS.
18	MR. KLEIN: MR. CHAIRMAN, I'M AWARE THAT
19	THERE'S AN EXTERNAL CONTRACT WITH KOCH, FOR EXAMPLE,
20	FOR INTELLECTUAL PROPERTY. AND WE HAVE JUST NOW
21	WITH THE FULL ADOPTION OF OUR INTELLECTUAL PROPERTY
22	STANDARDS FOR FOR-PROFITS HAVE A RAMP-UP TO DEAL
23	WITH ALL OF THOSE PROPOSALS. WE HAVE VERY
24	SIGNIFICANT INTEREST FROM THE FOR-PROFITS IN OUR NEW
25	GRANT ROUNDS, AND IT'S EXPECTED AND I THINK THIS
	10

1	BUDGET PLANS FOR THAT TO A SIGNIFICANT TIME
2	DEMAND ON NANCY KOCH IN INTELLECTUAL PROPERTY. I
3	KNOW THAT SHE IS THE PRINCIPAL OUTSIDE COUNSEL
4	ASSIGNED TO THE MEMORANDUMS OF UNDERSTANDING ALONG
5	WITH DR. TROUNSON.
6	CHAIRMAN GOLDBERG: THANK YOU. I'D LIKE
7	TO GO TO YOUR SITE, OS. YOU HAVE ANY QUESTIONS AS A
8	SUBCOMMITTEE MEMBER?
9	DR. STEWARD: NO QUESTIONS.
10	CHAIRMAN GOLDBERG: OKAY. MOVING UP THE
11	COAST, RI CARDO?
12	DR. AZZIZ: I HAVE TWO QUESTIONS. ONE'S A
13	MINOR QUESTION, AND I THINK IT WAS ALONG WHAT DUANE
14	HAD ASKED, BUT I DIDN'T QUITE GATHER EVERYTHING.
15	YOU DO HAVE A LARGE NUMBER OF SCIENTIFIC OFFICERS,
16	WHICH LOOKS LIKE PARTIAL FTE'S, TEN MONTHS, SIX
17	MONTHS, ETC., AND THE REASON FOR THAT, OBVIOUSLY
18	WE'RE HIRING THESE PEOPLE FULL TIME, IS JUST FOR THE
19	TIME THAT THEY'RE COMING IN. IS THAT IT?
20	MS. FERGUSON: YES, CORRECT.
21	DR. AZZIZ: BUT THEY ON THE SUBSEQUENT
22	BUDGET FOR '09-'10 ARE GOING TO BE 100, 12 MONTHS,
23	CORRECT?
24	MS. FERGUSON: CORRECT.
25	DR. AZZIZ: THE SECOND QUESTION IS A MORE
	20

20

1	GLOBAL QUESTION. AND THAT IS, WE HAVE AN OVERALL
2	INCREASE OF 46 PERCENT IN THE OPERATING BUDGET WHICH
3	MAY WELL BE CONSISTENT WITH THE GENERAL PLANNED
4	GROWTH OF THE AGENCY SINCE WE ARE STILL RELATIVELY
5	YOUNG. BUT I DID WANT TO GET YOUR SENSE AS TO
6	WHETHER THIS FITS IN WITH THE EARLY STRATEGIC PLANS
7	AS FAR AS GROWTH WAS CONCERNED.
8	CHAIRMAN GOLDBERG: I'D ASK CHAIRMAN KLEIN
9	TO ADDRESS THAT.
10	MR. KLEIN: DR. AZZIZ, WE'RE ACTUALLY
11	BEHIND ON THIS GROWTH OBVIOUSLY BECAUSE OF THE
12	LITIGATION; BUT IF YOU ADJUST FOR LITIGATION, THAT
13	WOULD BE REFLECTED IN THE ORIGINAL STRATEGIC PLANS
14	FOR THE RAMP-UP IN THE AGENCY STAFFING. AS CAN BE
15	SEEN, WE'RE OPERATING SUBSTANTIALLY BELOW THE BUDGET
16	CEILINGS THAT WERE SET. SO WE'RE ACHIEVING THE
17	RAMP-UP. OUR BUDGET IS INCREASING SIGNIFICANTLY,
18	BUT WE ARE SUBSTANTIALLY BELOW THE LEVEL THAT WOULD
19	HAVE BEEN EXPECTED FOR THIS LEVEL OF STAFFING.
20	DR. AZZIZ: SOUNDS GOOD. THAT'S MY SENSE.
21	I JUST WANT TO MAKE SURE THAT I WAS NOT MISREADING.
22	OKAY. THAT'S ALL I HAVE FROM MYSELF.
23	CHAIRMAN GOLDBERG: MARCY, ANY QUESTIONS?
24	MS. FEIT: NO. SO FAR EVERYBODY IS ASKING
25	THE SAME QUESTIONS I HAD. THE ONLY ONE, JUST TO TAG

1	ONTO WHAT DR. AZZIZ ASKED, IT WOULD BE HELPFUL IN
2	THE FUTURE, THEN, TO INCLUDE ANY COMMENTS REFERRING
3	BACK TO THE STRATEGIC PLAN SO WE COULD COMPARE WHERE
4	WE STAND WITH IT.
5	CHAIRMAN GOLDBERG: ALTHOUGH MY
6	UNDERSTANDING IS THE STRATEGIC PLAN WAS A SCIENTIFIC
7	STRATEGIC PLAN. IT DIDN'T INCLUDE AN OPERATIONS AND
8	ADMINISTRATION COMPONENT TO IT.
9	MR. KLEIN: I THINK THAT WHAT MARCY IS
10	REFERRING TO IS IN THE ORIGINAL INITIATIVE THERE WAS
11	A FINANCIAL STRATEGIC PLAN SUBMITTED TO THE
12	LEGISLATIVE ANALYST'S OFFICE, WHICH SHOWED A
13	FINANCIAL RAMP-UP. AND WE COULD CERTAINLY PROVIDE A
14	COMPARISON TO THAT.
15	MS. FEIT: RIGHT. I THINK THAT WOULD BE
16	REAL HELPFUL FOR THE BOARD.
17	CHAIRMAN GOLDBERG: POINT WELL TAKEN. BOB
18	PRI CE.
19	DR. PRICE: UNLESS SOMEBODY HAS ALREADY
20	ASKED IT AND I MISSED IT, WOULD SOMEBODY EXPLAIN WHY
21	THE ALLOCATION FOR THE STANDARDS WORKING GROUP IS
22	EXPECTED TO QUADRUPLE?
23	MS. FERGUSON: IN THE STANDARDS WORKING
24	GROUP, THE INFORMATION THAT I RECEIVED FROM THE
25	SCIENCE OFFICE INDICATED THAT THERE WOULD BE
	22

1	ADDITIONAL MEETINGS, AND ACTUALLY THE COST INCREASES
2	REALLY ARE THE COST OF VENUES, TRANSPORTATION,
3	BRINGING IN THE REVIEWERS. ALL OF THAT COST HAS
4	INCREASED SIGNIFICANTLY.
5	DR. PRICE: I'M JUST SURPRISED BECAUSE I
6	THOUGHT THAT THAT WORKING GROUPS'S WORK HAD BEEN
7	PRETTY MUCH DONE ALREADY.
8	CHAIRMAN GOLDBERG: JEFF SHEEHY IS ON THE
9	COMMITTEE AND THE WORKING GROUP, AND HE'D LIKE TO
10	MAKE A COMMENT.
11	MR. SHEEHY: THAT'S KIND OF WHAT WE WE
12	DID THE FIRST ROUND OF DOING THE ETHICAL STANDARDS,
13	BUT WE ACTUALLY HAVE TWO MAJOR ISSUES THAT ARE
14	EMERGING THAT I THINK WE REALLY NEED TO GET A HANDLE
15	ON. ONE IS THE ISSUE OF EGG DONATION. AND, YOU
16	KNOW, WE'VE HEARD FROM DOUG MELTON AND KEVIN EGGAN,
17	WHO HAVE BEEN WORKING ON THIS ISSUE AT HARVARD, THAT
18	IT'S BEEN VERY CHALLENGING FOR THEM. SO WE NEED TO
19	FIGURE OUT HOW TO ACCOMPLISH OUR GOAL OF MOVING THE
20	SCIENCE FORWARD WITHIN AN ETHICAL CONTEXT.
21	SO I THINK THAT'S GOING TO TAKE A BIT OF
22	WORK. AND THE OTHER THING THAT'S COME UP IS THE
23	CONDUCT OF CLINICAL TRIALS. WE HAD A VERY
24	INTERESTING PRESENTATION BY JOHN WAGNER, WHO'S A
25	MEMBER OF THE WORKING GROUP, ON A CLINICAL TRIAL

1	THAT HE STARTED THAT HAS HAD, FRANKLY, PHENOMENAL
2	RESULTS. IT'S ACTUALLY SAVING THESE KIDS' LIVES WHO
3	HAVE THIS DREADFUL DISEASE.
4	AND IN THE COURSE OF DESCRIBING WHAT HE
5	HAD GONE THROUGH TO INITIATE, A WHOLE HOST OF
6	ETHICAL ISSUES WERE IDENTIFIED. AND THEY'RE ONES
7	THAT ARE BEYOND THOSE THAT JOHN BROUGHT UP THAT ARE
8	KIND OF ENDEMIC TO ALL CLINICAL TRIALS. AS WE GET
9	CLOSER TO THE CLINIC, WE NEED TO BE IN A POSITION
10	IT'S BETTER THAT WE'RE PREPARED.
11	I KNOW BERNIE LO, WHO IS CO-CHAIR, HAS
12	PROPOSED PERHAPS AN ALL-DAY MEETING JUST ON THE
13	ISSUES THAT WE'RE GOING TO CONFRONT IN CLINICAL
14	TRIALS. WHO GETS TO BE IN A CLINICAL TRIAL IS AN
15	ISSUE. YOU KNOW, I KNOW IN AIDS WE'VE SEEN THIS.
16	CLINICAL TRIAL, YOU JUST DON'T GO OUT AND DO A
17	CLINICAL TRIAL. THE ETHICS INVOLVED, INFORMED
18	CONSENT THAT'S INVOLVED, IT CAN BE A MORE COMPLEX
19	PROCESS.
20	MR. KLEIN: TO AUGMENT JEFF'S STATEMENTS,
21	THERE'S CONCERN THAT AT THE FDA ADVISORY GROUP
22	HEARING THERE WERE COMMENTS BY INDIVIDUAL MEMBERS OF
23	THE ADVISORY GROUP, WHICH ARE NOT BINDING ON THE
24	FDA, THAT UNLESS THERE WAS IMMINENT RISK TO LIFE,
25	THAT POTENTIALLY THE FDA, IN BALANCING THE RISK OF

1	EMBRYONIC STEM CELL CLINICAL TRIALS, MIGHT WANT TO
2	DEFER HAVING ANY EMBRYONIC STEM CELL TRIALS IN THOSE
3	AREAS AND RESTRICT THEM TO AREAS WHERE THERE WASN'T
4	IMMINENT RISK TO LIFE.
5	AND THE COALITION FOR THE ADVANCE OF
6	MEDICAL RESEARCH AND OTHER ORGANIZATIONS
7	REPRESENTING PATIENTS CERTAINLY BELIEVE THAT WE
8	SHOULD PUT ON THE TABLE THE POINT OF VIEW THAT
9	PATIENTS PROPERLY INFORMED BY THEIR PHYSICIANS,
10	PROPERLY INFORMED BY SCIENCE WITH RIGOROUS FDA
11	REVIEW, IF THEY ARE PATIENTS WITH CHRONIC DISEASE,
12	THAT THERE SHOULD BE PERMISSION FOR FDA TRIALS ON
13	EMBRYONIC STEM CELL THERAPIES.
14	I KNOW JEFF RELATES BACK TO THE HIV
15	HISTORY WHERE THERE WERE SOME REASONABLE RISKS TAKEN
16	THAT WERE NOT ALWAYS WITH POSITIVE OUTCOMES, BUT
17	THOSE RISKS WERE ESSENTIAL TO SAVING LIVES IN THE
18	FUTURE AND LED TO BRILLIANT BREAKTHROUGHS THAT HAVE
19	BEEN REMARKABLE IN TURNING AROUND THE MEDICAL
20	IMPACTS OF HIV/AIDS.
21	MR. SHEEHY: I CAN GIVE YOU RIGHT OFF THE
22	TOP OF MY HEAD, DR. PRICE, AN ISSUE THAT IS
23	RELATIVELY SIMPLE. WHEN IS A PLACEBO-CONTROLLED
24	TRIAL APPROPRIATE? LIKE RIGHT NOW IN HIV, FOR ANY
24 25	TRIAL APPROPRIATE? LIKE RIGHT NOW IN HIV, FOR ANY NEW ANTIRETROVIRAL PRODUCT, WE WOULD NOT ALLOW A

1	PLACEBO TRIAL. IT'S JUST NOT ETHICALLY APPROPRIATE
2	IN HIV FOR NEW DRUGS NOW. SO WHEN IS IT APPROPRIATE
3	TO DO A PLACEBO? IT'S JUST ONE INTERESTING ISSUE
4	THAT HASN'T BEEN THOUGHT ABOUT IN THIS CONTEXT YET.
5	CHAIRMAN GOLDBERG: ANY OTHER QUESTIONS,
6	DR. PRI CE?
7	MS. FERGUSON: MY UNDERSTANDING IS, IN
8	ADDITION, THERE ARE SITE VISITS THAT HAVE TO BE
9	CONDUCTED TO ENSURE COMPLIANCE.
10	CHAIRMAN GOLDBERG: THAT'S RIGHT. GOOD
11	POI NT.
12	MR. KLEIN: WAS THAT DR. PRICE'S QUESTION
13	OR DR. STEWARD'S QUESTION?
14	CHAIRMAN GOLDBERG: THAT WAS DR. PRICE'S
15	QUESTI ON.
16	DR. PRICE: ALL RIGHT. I'M DONE.
17	CHAIRMAN GOLDBERG: THANK YOU. I'D LIKE
18	TO NOW TURN IT OVER TO THE PUBLIC, AND WE'LL GO SITE
19	BY SITE STARTING HERE AT THE CIRM AND THEN MOVING TO
20	THE SOUTHERN PART OF THE STATE AND UP THE COAST.
21	PLEASE ANNOUNCE YOURSELF FOR THE TRANSCRIPTIONIST.
22	MR. REED: THIS IS DON REED. THE TRAVEL
23	IS CRUCIAL AS SEED MONEY FOR THE MATCHING GRANTS.
24	TO GIVE A PERSONAL CONTEXT TO IT, I JUST GOT SOME
25	FIGURES TODAY. THE ROMAN REED SPINAL CORD INJURY
	24

1	PROGRAM, SINCE ITS INCEPTION EIGHT YEARS AGO, HAS
2	SPENT A TOTAL OF \$12.5 MILLION ON RESEARCH, BUT THE
3	PROGRAM ATTRACTED \$50 MILLION IN ADDITIONAL GRANTS,
4	SO THE 12 MILLION BY VIRTUE OF MATCHING GRANTS
5	BECAME 62 MILLION FOR CALIFORNIA.
6	I SUSPECT THIS IS GOING TO BE THE CASE FOR
7	THE STEM CELL PROGRAM, BUT WE DO TEND TO SPEND EXTRA
8	MONEY TO SEND OUR SCIENTISTS SO THEY CAN BE INVOLVED
9	IN THE CUTTING EDGE RESEARCH WHEREVER IT IS IN THE
10	WORLD.
11	CHAIRMAN GOLDBERG: THANK YOU. ANY OTHER
12	QUESTIONS FROM THE PUBLIC IN SAN FRANCISCO?
13	MR. JENSON: DAVE JENSON, CALIFORNIA STEM
14	CELL REPORT. THE FUND ALLOCATIONS FOR PROPOSITION
15	71, DIRECT RESEARCH LEGAL, IT'S \$1.8 MILLION FOR THE
16	CURRENT FISCAL YEAR, CORRECT?
17	MS. FERGUSON: CORRECT.
18	MR. JENSON: THAT'S UP FROM \$1.2 MILLION
19	LEGAL EXPENSES FOR CURRENT FISCAL YEAR?
20	MS. FERGUSON: YES.
21	MR. JENSON: DOES THAT REPRESENT ALL LEGAL
22	COSTS THAT CIRM HAS?
23	MS. FERGUSON: YES, IT DOES.
24	CHAIRMAN GOLDBERG: WE'LL GO TO YOUR SITE,
25	FLOYD. DO YOU HAVE MEMBERS OF THE PUBLIC?
	27

1	DR. BLOOM: NO, WE DON'T.
2	CHAIRMAN GOLDBERG: GENOPTIX SITE?
3	DR. NOVA: NO ONE FROM THE PUBLIC.
4	CHAIRMAN GOLDBERG: DUANE'S SITE?
5	MS. KING: NO ONE FROM THE PUBLIC.
6	CHAIRMAN GOLDBERG: IRVINE?
7	DR. STEWARD: NO PUBLIC.
8	CHAIRMAN GOLDBERG: CEDARS?
9	MR. SIMPSON: PUBLIC. THIS IS JOHN
10	SIMPSON. I DO THINK THIS IS A WONDERFUL TOP-LINE
11	BUDGET, BUT ONE OF THE THINGS THAT CONCERNS ME, TWO
12	POINTS. ONE, I HAD A GREAT DEAL OF DIFFICULTY
13	RECONCILING IT WITH YOUR ORGANIZATIONAL CHART. IN
14	OTHER WORDS, YOU SEEM TO TALK ABOUT DIFFERENT COST
15	CENTERS AND CALL THEM BY DIFFERENT NAMES. IN YOUR
16	ORGANIZATIONAL CHART YOU TALK ABOUT THE OFFICE OF
17	THE CHIEF OPERATING OFFICER. I GUESS THAT
18	TRANSLATES INTO THE OFFICE OF ADMINISTRATION, BUT
19	IT'S A LITTLE VAGUE. I WONDER IF YOU'RE GOING TO
20	RECONCILE THOSE TWO THINGS AND BRING THEM TOGETHER
21	AT SOME POINT.
22	THE SECOND ISSUE HAS TO DO WITH I THINK
23	IT'S AN EXCELLENT TOP LINE. YOU DON'T LIST ENOUGH
24	OF YOUR ASSUMPTIONS TO UNDERSTAND WHAT'S GOING ON.
25	I UNDERSTAND AND AM SYMPATHETIC TO THE NOTION OF THE

1	NEED FOR TRAVEL, BUT I REALLY THINK THE PUBLIC NEEDS
2	TO KNOW WHAT ASSUMPTIONS YOU ARE MAKING. I SORT OF
3	DID A LITTLE BIT OF GUESSWORK MYSELF AND SAID, WELL,
4	IF THE AVERAGE TRIP IS \$3,000, THEN THAT WOULD BE 87
5	TRIPS. FOR THE SCIENTISTS, IT WOULD BE 48 TRIPS FOR
6	THE OFFICE OF THE CHAIRMAN. I DON'T KNOW EXACTLY
7	WHETHER THAT IS APPROPRIATE OR INAPPROPRIATE, BUT I
8	DO THINK YOU NEED TO BE EXPLICIT ABOUT THOSE
9	ASSUMPTIONS THAT YOU'RE MAKING.
10	AND THE SAME THING AGAIN WITH THE EXTERNAL
11	GRANTS EXTERNAL CONTRACTS. I THINK IT WOULD BE
12	VERY HELPFUL IF YOU COULD INCLUDE A SUPPORTING
13	DOCUMENT THAT LISTS WHAT THEY'RE ANTICIPATED TO BE.
14	FINALLY, TWO OTHER POINTS. I DON'T
15	UNDERSTAND WHY THE STANDARDS ALLOCATION IS ALLOCATED
16	TO THE OFFICE OF ADMINISTRATION WHEN THE STANDARDS
17	OFFICER IS WORKING IN THE SCIENCE OFFICE. SO I
18	DON'T UNDERSTAND WHY THE WORKING GROUP GETS
19	ALLOCATED THERE.
20	AND THE FINAL POINT WOULD BE A QUESTION.
21	DOES THIS BUDGET PROVIDE ANY SORT OF SALARY FUNDING
22	FOR EITHER THE VICE CHAIRMAN OR THE CHAIRMAN?
23	CHAIRMAN GOLDBERG: SHE'S TRYING TO
24	CATALOG YOUR QUESTIONS, JOHN.
25	MR. KLEIN: WHY DON'T YOU REPEAT YOUR LAST
	20

1	QUESTI ON, JOHN?
2	MR. SIMPSON: LAST QUESTION WAS DOES THE
3	BUDGET INCLUDE ANY FUNDS WE'RE ALL THANKFUL THAT
4	BOTH THE CHAIRMAN AND VICE CHAIRMAN CURRENTLY
5	DECLINE TO ACCEPT SALARIES, BUT I BELIEVE PEOPLE
6	SHOULD BE PAID WHAT THEY'RE ENTITLED TO. SO MY
7	QUESTION IS DOES THIS BUDGET INCLUDE ANY SALARY
8	FUNDS FOR EITHER THE CHAIRMAN OR THE VICE CHAIRMAN?
9	MS. FERGUSON: NO, IT DOES NOT.
10	MR. SIMPSON: THE OTHER COMMENTS WERE JUST
11	SORT OF SEEKING FURTHER EXPLANATION OF THE
12	ASSUMPTIONS THAT WENT INTO YOUR TRAVEL BUDGETING.
13	MS. FERGUSON: POINT WELL TAKEN. AND THE
14	ACTUAL ANSWER TO YOUR LAST QUESTION ABOUT THE VICE
15	CHAIR AND THE CHAIR, THERE ARE NO FUNDS PROVIDED IN
16	THIS BUDGET FOR A SALARY FOR EITHER ONE OF THOSE TWO
17	POSITIONS.
18	MR. KLEIN: THIS IS BOB KLEIN. I
19	APPRECIATE YOUR COMMENTS. I PERSONALLY WOULD, AS A
20	MATTER OF PREFERENCE, PREFER TO SEE NONTAXPAYER
21	DOLLARS USED FOR PAYMENT OF THOSE SALARIES. I'VE
22	BEEN KNOWN TO RAISE FUNDS BEFORE, BUT IT IS A GREAT
23	BENEFIT TO SEE THE TAXPAYER DOLLARS GOING TO THE
24	MEDICAL RESEARCH AND TO THE CORE SCIENTIFIC STAFF.
25	BUT IT IS TRUE THAT AT SOME POINT THIS ISSUE NEEDS
	30

1	TO BE ADDRESSED BECAUSE RESOURCES ARE LIMITED. I DO
2	APPRECIATE YOUR COMMENT. AND CERTAINLY IF YOU'D
3	LIKE TO WRITE A CHECK FOR THAT PURPOSE, I WOULD LIKE
4	TO WRITE IN YOUR BLOG TO THANK YOU.
5	CHAIRMAN GOLDBERG: MARCY FEIT, ARE THERE
6	ANY MEMBERS OF THE PUBLIC AT YOUR SITE?
7	MS. FEIT: NO PUBLIC.
8	CHAIRMAN GOLDBERG: BOB PRICE, ANY MEMBERS
9	OF THE PUBLIC?
10	DR. PRICE: NO, THERE ARE NO MEMBERS HERE.
11	CHAIRMAN GOLDBERG: OKAY. SO WHAT I SAID
12	WE WOULD DO IS A KIND OF OPEN DISCUSSION TO THE
13	BOARD AND THEN TO THE PUBLIC FOR MORE THAN SPECIFIC
14	QUESTIONS ABOUT THE BUDGET, BUT ANY COMMENTS IN
15	GENERAL ABOUT THE BUDGET, ABOUT THE BUDGET PROCESS.
16	OUR GOAL AS A SUBCOMMITTEE IS TO MAKE A
17	RECOMMENDATION TO THE BOARD TO THE LCOC AT OUR
18	MEETING NEXT WEEK EITHER IN SUPPORT OF THIS PROPOSAL
19	OR A MODIFIED FORM OF IT. SO I THINK THE GOAL OF
20	OUR MEETING OUGHT TO BE TO TRY TO GET TO SUCH A
21	RESOLUTI ON.
22	MR. KLEIN: MR. CHAIRMAN, WILL YOU
23	ENTERTAIN A MOTION?
24	CHAIRMAN GOLDBERG: YES.
25	MR. KLEIN: I'D LIKE TO MAKE A MOTION THAT
	31

	DANNISTERS REPORTING SERVICE
1	WE RECOMMEND THIS BUDGET FOR APPROVAL. AND TO BE
2	RESPONSIVE TO MR. SIMPSON'S COMMENTS, I'M HAPPY TO
3	PROVIDE A DETAIL OF THE ASSUMPTIONS FOR THE OFFICE
4	OF THE CHAIR ON TRAVEL AS A SUPPLEMENTAL DETAIL. I
5	CAN'T SPEAK FOR OTHER DEPARTMENTS WHO HAVE
6	THOUGHTFULLY LOOKED AT THEIR BUDGET ESTIMATES, BUT
7	THEY' RE JUST NOT PRESENT.
8	CHAIRMAN GOLDBERG: WE HAVE A SECOND?
9	DR. BLOOM: SECOND.
10	CHAIRMAN GOLDBERG: SHOULD WE DO A ROLL
11	CALL, JAMES?
12	MR. HARRISON: YES.
13	MS. KING: RICARDO AZZIZ.
14	DR. AZZIZ: I'M SORRY. I WAS ON MUTE. DO
15	YOU WANT TO REPEAT THAT QUESTION?
16	MR. KLEIN: THERE'S A MOTION ON THE FLOOR
17	TO RECOMMEND THIS BUDGET TO THE BOARD.
18	DR. AZZIZ: SO YOU'RE GOING THROUGH A
19	VOTE. APPROVED OR SUPPORT OR YES.
20	MS. KING: DR. PRICE.
21	DR. PRICE: I'LL TRY YES.
22	MS. KING: DR. BLOOM.
23	DR. BLOOM: YES.
24	MS. KING: MICHAEL GOLDBERG.
25	CHAIRMAN GOLDBERG: YES.
	22
	32

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

ĺ	
1	MS. KING: BOB KLEIN.
2	MR. KLEIN: YES.
3	MS. KING: TINA NOVA.
4	DR. NOVA: YES.
5	MS. KING: DUANE ROTH.
6	MR. ROTH: YES.
7	MS. KING: JEFF SHEEHY.
8	MR. SHEEHY: YES.
9	MS. KING: OS STEWARD.
10	DR. STEWARD: YES.
11	MS. KING: THAT MOTION CARRIES.
12	MS. FEIT: YOU MISSED MARCY FEIT.
13	MS. KING: I'M SORRY. MARCY FEIT. MARCY?
14	MS. FEIT: YES.
15	CHAIRMAN GOLDBERG: I'D LIKE TO PROCEED
16	THE MOTION PASSES. I'D LIKE TO PROCEED TO ITEM NO.
17	4, AND I'D LIKE TO ASK CHAIRMAN KLEIN TO ADDRESS
18	THAT.
19	MR. KLEIN: I'LL TRY AND COVER SOME OF THE
20	POLICY QUESTIONS THAT THE LOAN TASK FORCE HAS PUT
21	FORWARD. BUT SINCE DUANE JOINED THE CALL, WHICH WE
22	WERE NOT CERTAIN, DUANE, WHETHER YOU COULD, I THINK
23	IT WOULD BE APPROPRIATE FOR YOU TO LEAD OFF AND
24	ADDRESS THE POLICY QUESTIONS THAT YOU'RE LOOKING TO
25	THIS FINANCE COMMITTEE AS A WHOLE TO ADDRESS. AND
	33
	აა

1	THEN I HAVE SOME COMMENTS THAT DR. PENHOET HAD THAT
2	I WILL AUGMENT YOURS WITH.
3	MR. ROTH: ALL RIGHT. SO LAST FULL BOARD
4	MEETING I SUMMARIZED WHERE WE STOOD ON WHAT OUR
5	RECOMMENDATION TO THIS COMMITTEE WOULD BE. AND IT
6	INCLUDED THE SEPARATION OF THE AMOUNTS AND CERTAIN
7	CRITERIA THAT WOULD BE DEALT WITH IN TERMS OF THE
8	RFA PROCESS AND THE TERMS THAT WOULD BE INCLUDED IF
9	AND WHEN THERE'S AN RFA THAT INCLUDES LOANS.
10	ONCE WE MADE THAT SEPARATION, MANY OF THE
11	THINGS THAT WE WERE DISCUSSING PREVIOUSLY DROPPED
12	OUT, AND WE'RE DEALING WITH THOSE ONLY ONCE THERE IS
13	A LOAN PROGRAM. AND THERE ARE OPTIONS AVAILABLE,
14	RECOMMENDATION IS ANYWAY, THERE ARE OPTIONS
15	AVAILABLE TO CHOOSE RECOURSE OR NONRECOURSE LOAN, TO
16	SELECT A TERM OF AN OPTION OF THE TERM THAT YOU
17	WOULD LIKE IT TO COVER, AND EARLY ACCELERATION IF
18	IT'S A LONGER TERM, AND THAT WOULD BE AT A DIFFERENT
19	POTENTIAL INTEREST RATE THAN THE SHORTER TERM LOANS.
20	SO MANY OF THE THINGS WE DEALT WITH, I
21	THINK, ARE FAIRLY EASY TO MAKE A DECISION ON POLICY
22	ISSUES. WHERE WE RAN INTO PROBLEMS WERE ALLOCATION,
23	HOW MUCH OF THE PROGRAM, ETC., WHAT STAGE IT SHOULD
24	BE, ALL OF WHICH NEEDS TO BE DEALT WITH ON AN RFA
25	BASIS AND POLICY BASIS.
	2.4

1	WITHOUT GETTING INTO SPECIFICS, BOB, I'M
2	GOING TO LEAVE IT THERE AND LET YOU
3	MR. KLEIN: THANK YOU VERY MUCH, DUANE.
4	AND, DUANE, WE TREMENDOUSLY APPRECIATE THE STRUCTURE
5	AND THOUGHT THAT WENT INTO THE LOAN PROGRAM AND THE
6	ANALYSIS OF THE CONSULTANTS THAT YOU GUIDED IN THAT
7	PROCESS.
8	AT THIS MEETING, MY UNDERSTANDING, MR.
9	CHAIRMAN, IS JUST PUTTING THE ISSUES ON THE TABLE SO
10	THE PUBLIC HAS AN IDEA AND MEMBERS OF THE COMMITTEE
11	HAVE AN IDEA OF THE ISSUES WE'RE GOING TO BE FACING
12	IN THE NEXT MEETING.
13	CHAIRMAN GOLDBERG: THAT'S CORRECT.
14	MR. KLEIN: SO IN THAT CONTEXT, AS DUANE
15	SAID, THE PORTFOLIO SIZE THAT WE COMMIT TO IS GOING
16	TO BE CRITICALLY IMPORTANT BECAUSE IF THE TOTAL
17	PORTFOLIO OVER A PERIOD OF THREE OR FOUR YEARS WERE
18	A HUNDRED MILLION, THEN IT WOULD ESSENTIALLY SIZE
19	DOWN THE MAXIMUM LOAN YOU WOULD MAKE FOR ANY
20	INDIVIDUAL LOAN BECAUSE OF CONCENTRATIONS OF RISK
21	ISSUES AS TO BASED ON THE RELEVANT SIZE OF ANY
22	INDIVIDUAL LOAN TO OVERALL PORTFOLIO SIZE.
23	IF THE PORTFOLIO WERE \$500 MILLION TARGET
24	OVER FOUR YEARS, THAT ALLOWS A SIGNIFICANTLY HIGHER
25	INDIVIDUAL LOAN AMOUNT. AND ED PENHOET SPECIFICALLY

1	HAD WANTED TO MAKE SURE THAT THE ISSUE WAS ON THE
2	TABLE THAT FOR GOING INTO HUMAN CLINICAL TRIALS AND
3	EMBRYONIC STEM CELL RESEARCH IN PARTICULAR, BECAUSE
4	OF THE HISTORY OF THIS RESEARCH AND THE DEARTH OF
5	CAPITAL IN THIS SPACE, THAT IT MAY TAKE A VERY
6	SIGNIFICANTLY SIZED LOAN EVEN ON A MATCHING FUND
7	BASIS FOR COMPANIES TO GET THROUGH THE PRECLINICAL,
8	PHASE I, AND PHASE II, AND PHASE II B STAGE BEFORE
9	PRIVATE CAPITAL WOULD BE PREPARED TO STEP IN
10	SO THAT EVEN IF IT'S MILESTONE DRIVEN, AND
11	INDIVIDUAL LOANS MIGHT HAVE INCREMENTS OF ONE
12	MILLION, THREE MILLION, FIVE MILLION AT DIFFERENT
13	MILESTONES, THE AGGREGATED TOTAL LOAN COMMITMENT ON
14	AN INDIVIDUAL PROGRAM, WHICH WOULD HAVE TO GO
15	THROUGH PEER REVIEW, COULD HAVE TO BE FAIRLY
16	SI GNI FI CANT.
17	NOW, THAT ARGUES, IF IT IS APPROPRIATE,
18	FOR A FAIRLY FOR THE LARGER PORTFOLIO SIZE. AND
19	BEFORE THE NEXT MEETING, MAYBE THE COMMITTEE MEMBERS
20	CAN LOOK AT THE PWC RISK ANALYSIS BECAUSE THAT RISK
21	ANALYSIS SUGGESTS THAT EVEN WITH VERY SUBSTANTIAL
22	LOSSES AND A CONSERVATIVE SUCCESS RATE THAT, BECAUSE
23	OF WARRANTS THAT WOULD BE ATTACHED TO THESE LOANS
24	WHERE THERE WAS SUCCESS AND BECAUSE OF INTEREST
25	COLLECTED FROM THESE LOANS, THAT WITH A SIGNIFICANT

1	SIZE PORTFOLIO, WE COULD HAVE CAPITAL WE COULD
2	HAVE CAPITAL SURVIVAL AND HAVE AN EVERGREEN FUND
3	THAT ACTUALLY GREW OVER TIME, WHICH WOULD SEEM TO
4	INDICATE THAT A REASONABLE ALLOCATION OF ASSETS TO
5	THIS PURPOSE WOULD BE AN APPROPRIATE RISK DECISION.
6	BUT THOSE ARE THE KINDS OF DECISIONS THAT
7	HOPEFULLY AFTER REVIEWING THE MATERIAL AND WITH
8	PREPARATORY MATERIAL THAT WOULD BE SENT OUT BEFORE
9	THE NEXT MEETING THAT WILL BE VITAL TO DECIDE. I
10	THINK THE GOAL IS BY THE AUGUST BOARD MEETING TO BE
11	ABLE TO HAVE A POLICY THAT WOULD BE APPROVED WITH
12	THE WORK THAT HAS BEEN DONE BY THE LOAN TASK FORCE
13	AND WITH DECISIONS BEING MADE ON HOW WE'RE GOING TO
14	DEAL WITH FINANCIAL UNDERWRITING.
15	THERE'S BEEN DISCUSSION PREVIOUSLY AND
16	WE'RE GOING TO TRY AND BRING IN SILICON VALLEY BANK
17	AND OTHERS IN THE FIELD WITH PROPOSALS AND IDEAS
18	ABOUT DELEGATED UNDERWRITING MODELS SIMILAR TO THE
19	FNMA DELEGATED UNDERWRITING MODELS WHERE YOU CAN
20	CONTRACT WITH PRIVATE COMPANIES, IN THIS CASE BANKS
21	AND INSTITUTIONS THAT ARE EXPERT IN BIOTECH LOANS,
22	AND HAVE THEM DO THE FINANCIAL UNDERWRITING AND
23	STRUCTURING UNDER THE SUPERVISION OF A STAFF MEMBER
24	BECAUSE WE DON'T HAVE THE INTERNAL STAFFING CAPACITY
25	TO BRING THAT IN-HOUSE. AND IF WE DID, IT WOULD

1	TAKE US TOO LONG TO DEVELOP THE EXPERTISE.
2	SO THE METHOD OF STAFFING THIS TO MINIMIZE
3	OUR INTERNAL ADMINISTRATIVE LOAN WHILE GETTING THE
4	GREATEST EXPERTISE IN ADMINISTRATION AND OVERSIGHT
5	AND UNDERWRITING IS ANOTHER CATEGORY OF POLICIES TO
6	BE DI SCUSSED.
7	CHAIRMAN GOLDBERG: THANK YOU. I'D LIKE
8	TO OPEN IT UP TO COMMENT FIRST TO SUBCOMMITTEE
9	MEMBERS AND THEN THE PUBLIC. DR. BLOOM?
10	DR. BLOOM: NO COMMENT. VERY CLEAR.
11	CHAIRMAN GOLDBERG: TINA? DUANE?
12	MR. ROTH: I DON'T THINK I DO AT THIS
13	POINT. YOU'RE NOT ASKING FOR ANYTHING IN TERMS OF
14	ACTION. YOU'RE JUST MAKING SOME GENERAL COMMENTS,
15	BOB, THAT YOU WANT TO HAVE MORE INFORMATION COMING
16	FORWARD.
17	MR. KLEIN: JUST TO OUTLINE THINGS THAT
18	WILL BE COMING UP FOR DISCUSSION ON THE AGENDA.
19	MR. ROTH: I WILL JUST PUT ONE NOTE IN
20	THERE ABOUT THE DESIGNATED UNDERWRITER, THAT I HAVE
21	SOME CONCERNS ABOUT CONFLICT OF INTEREST THAT ARE
22	GOING TO HAVE TO BE ADDRESSED. THEY ARE IN THIS
23	BUSINESS. AS A RESULT OF BEING IN THIS BUSINESS, I
24	HAVE CONCERNS ON OUR SIDE THAT WE CAREFULLY HANDLE
25	THAT SO THAT THEY AREN'T UNDULY INFLUENCED AND VICE

1	VERSA. I THINK JUST AS WE ARE VERY CAREFUL TO MAKE
2	SURE, AS BEST AS WE CAN ANYWAY, THAT PEOPLE ARE NOT
3	CONFLICTED FOR MAKING DECISIONS ABOUT WHAT TO INVEST
4	IN AND WHAT NOT TO INVEST IN, SO THAT TO ME IS
5	SOMETHING THAT WE HAVE TO BE REALLY VERY COGNIZANT
6	OF.
7	CHAIRMAN GOLDBERG: OS?
8	DR. STEWARD: NO COMMENT.
9	CHAIRMAN GOLDBERG: MARCY?
10	DR. NOVA: I DIDN'T HAVE ANYTHING. I
11	APOLOGIZE FOR MISSING THE BUTTON.
12	CHAIRMAN GOLDBERG: MARCY?
13	MS. FEIT: NO COMMENT.
14	CHAIRMAN GOLDBERG: BOB PRICE?
15	DR. PRICE: NO COMMENT.
16	CHAIRMAN GOLDBERG: OKAY. I'D LIKE TO
17	OPEN IT UP TO MEMBERS OH, I APOLOGIZE. JEFF
18	SHEEHY.
19	MR. SHEEHY: WELL, I HAD ONE COMMENT. AND
20	I GUESS IT WOULD BE BETTER TO HAVE THIS IN MIND
21	GOING FORWARD. I WOULD FEEL MORE COMFORTABLE IF
22	WE'RE GOING TO TALK ABOUT A FIGURE OF, SAY, HALF A
23	BILLIONS DOLLARS, NOT ALLOCATING THAT ALL AT ONCE.
24	YOU KNOW, THIS IS GOING TO BE A NEW PROGRAM. AND IN
25	PRINCIPLE I'VE SEEN THE NUMBERS, NOT BEING A
	30

1	FINANCIAL PERSON, BUI II DOES MAKE SENSE THAT YOU
2	HAVE TO PUT ENOUGH INTO THE POT TO BE ABLE TO GET
3	ENOUGH WIND. BUT WE'RE NOT GOING TO DO THIS ALL IN
4	ONE YEAR.
5	MAYBE WHAT I WOULD FEEL MUCH MORE
6	COMFORTABLE WITH IS SOMETHING THAT ANTICIPATED, AND
7	WE CAN'T KNOW UNTIL WE GET THE APPLICATIONS AND IT
8	GETS APPROVED, A CERTAIN AMOUNT ON AN ANNUAL BASIS
9	WITH SOME SORT OF FEEDBACK TO SEE HOW OUR PROCESS
10	WORKS. FIRST COUPLE YEARS WE'RE REALLY GOING TO
11	WANT TO KNOW HOW THE PROCESS IS WORKING. WE'RE NOT
12	GOING TO HAVE ANY REAL RESULTS. AND MAYBE BRINGING
13	IT BACK FOR, NOT NECESSARILY DOING A GLOBAL APPROVAL
14	OF 500 MILLION OVER FOUR YEARS, BUT SAYING OUR
15	TARGET IS X NUMBER OF DOLLARS OVER ONE YEAR, FOLLOW
16	UP WITH A REAPPROVAL FOR ANOTHER YEAR WITH A
17	REAPPROVAL FOR ANOTHER YEAR JUST SO THAT WE CAN KIND
18	OF TRACK AND HAVE SOME SORT OF FEEDBACK. WE'RE NOT
19	DOING IT ALL AT ONCE AND JUST SENDING THIS THING OFF
20	HURRIEDLY DOWN THE TRACKS.
21	I HAD ONE OTHER QUESTION. WHEN YOU'RE
22	TALKING ABOUT THE CLINICAL TRIAL, WHAT IS THE
23	BALLPARK NUMBER YOU'RE GOING TO BE THINKING ABOUT?
24	YOU SAID ONE TO THREE. ARE WE TALKING ABOUT \$20
25	MILLION, \$10 MILLION? WHAT DO YOU THINK IT'S GOING

1	TO REALLY TAKE? DOES ANYBODY HAVE AN ESTIMATE,
2	PHASE I, PHASE II? OBVIOUSLY CELLULAR THERAPY IS
3	GOING TO BE MORE EXPENSIVE THAN A LOT OF OTHER
4	TYPES.
5	MR. KLEIN: I'D ACTUALLY LIKE ED TO TRY
6	AND ADDRESS THAT IN THE NEXT MEETING, BUT CERTAINLY
7	IT'S SOMETHING TO BE ADDRESSED AT THE NEXT MEETING.
8	HOPEFULLY WE COULD DO A HYPOTHETICAL EXAMPLE.
9	THE KEY TO THIS, I THINK, JEFF, IS THE
10	DIRECTION YOU'RE GOING, IS IF WE SET A STRATEGIC
11	PORTFOLIO SIZE, THEN WE CAN DO A RISK ANALYSIS BASED
12	ON THAT SIZE, BUT IT'S ALL INCREMENTAL. SO IF YOU
13	SAY IN FOUR YEARS APPROXIMATE PORTFOLIO SIZE IS 500
14	MILLION, EACH INDIVIDUAL ACTION HAS TO COME THE
15	BOARD. AND IF THE PROGRAM IS NOT WORKING, THEN YOU
16	EITHER MODIFY THE PROGRAM OR DON'T CONTINUE IT. SO
17	YOU CONSTANTLY HAVE A CHECK SYSTEM, THE CONTROL,
18	BASED UPON REAL-TIME FEEDBACK OF WHAT'S COMING OUT
19	OF THE ANNUAL EXPERIENCE WITH THIS PROGRAM.
20	SO THIS IS SOMETHING THAT WE'D BE
21	MONITORING. THEY ALL HAVE TO GO THROUGH PEER
22	REVIEW. THEY ALL HAVE TO COME TO THE BOARD FOR
23	APPROVAL. AND IT GIVES US A LOT OF INCREMENTAL
24	CONTROL AS WE GO. WE'LL DEFINITELY LEARN AS WE GO,
25	AND THERE'LL DEFINITELY BE LOSSES, AND WE HAVE TO
	И1

1	LEARN FROM EVERY LOSS TO MAKE EVERY TAXPAYER DOLLAR
2	GO AS FAR AS POSSIBLE FOR EVERY PATIENT.
3	DR. AZZIZ: MICHAEL, THIS IS RICARDO. I
4	DON'T THINK YOU ASKED OUR CENTER. JUST FOR
5	COMPLETENESS, I HAVE NO COMMENTS.
6	CHAIRMAN GOLDBERG: I APOLOGIZE. I'D LIKE
7	TO OPEN IT UP TO THE PUBLIC FIRST AT THE SAN
8	FRANCISCO SITE AND THEN AT YOUR SITE, RICARDO.
9	MR. JENSON: DAVE JENSON FOR THE
10	CALIFORNIA STEM CELL REPORT. IT MIGHT BE USEFUL AT
11	SOME POINT, USEFUL, VERY USEFUL, FOR THIS AGENCY TO
12	EXPLAIN HOW A PROGRAM THAT ANTICIPATES DEFAULTS AT A
13	50-PERCENT RATE, HOW THAT PROGRAM CAN STILL TURN A
14	PROFIT. IT'S NOT READILY APPARENT FROM ANYTHING ON
15	THE PUBLIC RECORD IN TERMS THAT I THINK THE GENERAL
16	PUBLIC OR LEGISLATORS OR EVEN VERY WELL-INFORMED
17	PUBLIC CAN UNDERSTAND.
18	MR. KLEIN: ARE YOU REFERRING TO OUR
19	OVERALL GRANT AND LOAN PROGRAM?
20	MR. JENSON: I'M REFERRING TO THE LOAN
21	PROGRAM.
22	MR. KLEIN: OKAY. HAVE YOU SEEN THE PWC
23	PROJECTIONS THAT WERE IN THE TASK FORCE MEETING? SO
24	THOSE PROJECTIONS LAY OUT A STRATEGIC FLOW OF LOANS
25	WITH DEFAULT RATES FOR DIFFERENT CLASSES. AND, OF
	42

1	COURSE, OUR GOAL IS SO THAT WE HAVE A PUBLICLY
2	UNDERSTOOD GAME PLAN.
3	CHAIRMAN GOLDBERG: THANK YOU VERY MUCH.
4	DOES JOHN SIMPSON IN LOS ANGELES HAVE A COMMENT?
5	MR. SIMPSON: TWO QUICK ONES. I JUST
6	WANTED TO AGREE WITH MEMBER ROTH'S COMMENTS ABOUT
7	BEING VERY VIGILANT ABOUT HOW THE DESIGNATED
8	UNDERWRITERS WOULD WORK. I DO THINK THAT THAT'S A
9	POTENTIAL AREA FOR PROBLEMS AND WOULD LIKE TO SEE A
10	MUCH MORE THOROUGH DISCUSSION IN THE FUTURE ABOUT
11	HOW THAT WOULD ALL WORK.
12	AND I ALSO WAS VERY SYMPATHETIC TO MEMBER
13	SHEEHY'S COMMENTS ABOUT PHASING IT IN AND WHAT
14	CHAIRMAN KLEIN SAID ABOUT HOW THAT WOULD WORK, I
15	THINK, IS A VERY GOOD APPROACH. THANK YOU.
16	MR. ADAMS: THIS IS BILL ADAMS,
17	INTERNATIONAL STEM CELL. AS A SMALL FOR-PROFIT
18	COMPANY, WE'D LIKE TO SEE THE LOAN PROGRAM MATURE AS
19	QUICKLY AS POSSIBLE AND SEE WHETHER OR NOT OBVIOUSLY
20	WE AND OUR COMPATRIOTS FIT INTO IT. BASED ON THE
21	DISEASE TEAM RESULTS, WE'RE KIND OF SITTING ON THE
22	SIDELINES, AS MR. KLEIN KNOWS, TO KIND OF SEE WHAT
23	THE NEXT STEP IS GOING TO BE. THANK YOU.
24	CHAIRMAN GOLDBERG: THANK YOU. IF THERE
25	ARE NO FURTHER COMMENTS, IT APPEARS THAT WE'VE
	43

```
COMPLETED THE AGENDA, AND I'D LIKE TO CALL THE
 1
 2
      MEETING ADJOURNED. THANK YOU ALL VERY MUCH.
                      (THE MEETING WAS THEN ADJOURNED AT
 3
 4
      04: 41 P. M.)
 5
 6
 7
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
                                 44
```

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE FINANCE SUBCOMMITTEE OF THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD AT THE LOCATIONS INDICATED ON THE AGENDA ON JUNE 19, 2008, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152

BARRISTER'S REPORTING SERVICE

1072 BRISTOL STREET

SULTE 100

COSTA MESA, CALIFORNIA

(714) 444-4100